Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

Hagop M. Kantarjian; Deborah A. Thomas; Jeffrey L. Jorgensen; Elias Jabbour; Partow Kebriaei; Michael Rytting; Sergernne York; Farhad Ravandi; Monica Kwari; Stefan Faderl; Mary Beth Rios; Jörge E. Cortes; Luis Fayad; Robert Tarnai; Sa A. Wang; Richard Champlin; Anjali S. Advani; Susan O’Brien

doi:10.1016/s1470-2045(11)70386-2

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Deborah A. Thomas(The University of Texas MD Anderson Cancer Center), Jeffrey L. Jorgensen(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Michael Rytting(The University of Texas MD Anderson Cancer Center), Sergernne York(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Monica Kwari(The University of Texas MD Anderson Cancer Center), Stefan Faderl(The University of Texas MD Anderson Cancer Center), Mary Beth Rios(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Robert Tarnai(Pharmaceutical Product Development (United States)), Sa A. Wang(The University of Texas MD Anderson Cancer Center), Richard Champlin(The University of Texas MD Anderson Cancer Center), Anjali S. Advani(Cleveland Clinic), Susan O’Brien(The University of Texas MD Anderson Cancer Center)

The Lancet Oncology

February 20, 2012

10.1016/s1470-2045(11)70386-2

Cited by 411

Abstract

Related Papers

No related papers found

Powered by citation graph analysis